Cahill represented Merrill Lynch, Pierce, Fenner & Smith Incorporated as lead underwriter and the other underwriters in connection with the Initial Public Offering of 25,532,000 common shares of VWR Corporation (NASDAQ: VWR), a leading independent provider of laboratory products, services and solutions to the global life science, general research and applied markets, resulting in gross proceeds of $536,172,000. Proceeds were used to refinance existing indebtedness and for general corporate purposes.

Goodwin Procter attorneys recently advised PayChoice on its $157.8 million sale to Sage North America. The transaction is expected to close in October and is subject to customary closing conditions. More >>

As reported in The Wall Street Journal, The New York Times and other media outlets, UBM plc announced that it has entered into a definitive agreement to acquire Paul, Weiss client Advanstar Communications for $972 million in cash. UBM is a U.K.-headquartered communications and events business. Advanstar operates 54 trade shows and over 100 conferences annually, including Magic Marketplace, the largest U.S. fashion trade show. The transaction, which is expected to close by year end, will make UBM the largest events business in the United States. More >>

Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of AUD 650 million aggregate principal amount of 5% fixed-rate senior registered notes due 2021. The underwriters were Morgan Stanley & Co. International plc, Australia and New Zealand Banking Group Limited, National Australia Bank Limited and Mitsubishi UFJ Securities International plc. More >>

Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of €1.25 billion aggregate principal amount of 1.875% fixed-rate senior notes due 2023. The lead manager for the underwriters was Morgan Stanley & Co. International plc. More >>

Johnson & Johnson announced a definitive agreement to acquire Alios BioPharma, a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. Cravath represented Johnson & Johnson in the transaction. The closing is subject to clearance under the Hart‑Scott‑Rodino Antitrust Improvements Act and other customary closing conditions. The transaction is expected to close during the fourth quarter of 2014. More >>

Cahill represented Citigroup as sole-underwriter in connection with the secondary public offering of 17,500,000 shares of common stock by certain selling shareholders of Envision Healthcare Holdings, Inc. (NYSE: EVHC) , resulting in gross proceeds of $611,975,000. More >>